MARKET NEWS

Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate 
ENZYVANT Resubmits BLA to FDA for RVT-802 for Pediatric Congenital Athymia
Stirling Ultracold & Catalent Announce Partnership to Establish Energy-Efficient Cold Chain Capabilities for Biologics & Emerging Modalities
ImCheck Announces Initiation of US Enrollment in Phase 1/2a EVICTION Trial for ICT01
Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm

  FEATURED EDITORIAL

  COMPANY PROFILE

Headquartered in the heart of the Swiss Alps, Datwyler is a leading industrial supplier and key player in global markets for system-critical components in the healthcare, automotive, and general industry. The healthcare market segment provides state-of-the-art solutions for parenteral drug and medical device packaging. Datwyler is a leading manufacturer and a key player in the global healthcare world. The company’s state-of-the-art solutions for drug packaging and medical devices are built on over a century of experience. Within Datwyler’s healthcare offering provides a range of products and services, including the most advanced elastomer formulations, coatings, aluminum seals, and processing technologies. Partnering up with the world’s top pharmaceutical and medical companies, the company represents a vital link in the supply chain, standing by its mission to ensure patients’ safety and improve patients’ lives. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Vetter & Rentschler Biopharma Further Strengthen Strategic Alliance

Vetter & Rentschler Biopharma Further Strengthen Strategic Alliance

Rentschler Biopharma and Vetter, two globally operating Contract Development and Manufacturing Organizations (CDMOs), recently announced their strategic collaboration has taken key steps….

Daré Bioscience Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results

Daré Bioscience Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results

Daré Bioscience, Inc. recently announced that data from the DARE-BVFREE Phase 3 study of DARE-BV1, a thermosetting vaginal gel for the treatment of bacterial vaginosis, was….

InveniAI & Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration

InveniAI & Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration

InveniAI LLC recently announced a multi-target drug discovery collaboration with Shionogi & Co., Ltd.; the multi-year collaboration will combine InveniAI’s AI platform….

AavantiBio & Catalent Announce Partnership to Support Development & Manufacturing of Gene Therapies 

AavantiBio & Catalent Announce Partnership to Support Development & Manufacturing of Gene Therapies 

AavantiBio and Catalent recently announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA)….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 12 – Particle Design Technology
May 19 – Nasal Drug Delivery